US court says man with defibrillator can be executed despite concerns
The case before the Tennessee Supreme Court on Thursday concerned Byron Black, currently on death row after his conviction in a 1988 triple murder.
Black's execution has been delayed multiple times, but a date was set on August 5 for him to receive a lethal injection.
However, in July, his defence team argued the execution could not proceed without first deactivating Black's defibrillator, for fear it would continuously shock his heart as he passed away, resulting in an unnecessarily painful and prolonged death.
Davidson County Chancery Court Judge Russell Perkins previously ruled that Black's defibrillator would have to be removed prior to execution.
But the Tennessee Supreme Court overturned that decision, arguing that removing the defibrillator in advance would amount to a 'stay of execution'.
The state justices added that the lower court's order was invalid because it had exceeded its authority.
Kelley Henry, one of Black's attorneys, said that she is looking at the opinion before making a decision about next steps.
Lawyers for the state said on Wednesday that healthcare workers, many of whom view participation in the execution process as a violation of medical ethics, were not willing to facilitate the defibrillator's removal.
The court did not address concerns over whether possible complications to the execution caused by the device could violate Black's constitutional right against cruel and unusual punishment. It also left open the possibility that Black could still win a reprieve against his execution.
Botched executions have been a subject of debate for years in the US, one of the few Western countries that still uses capital punishment.
Capital punishment carried out through methods such as lethal injection and electrocution can be frequently error-prone, sometimes resulting in painful, drawn-out deaths for prisoners.
A 2022 report by the Death Penalty Information Center (DPIC) found that seven out of 22 attempted executions in the US were 'visibly problematic' and included 'executioner incompetence, failures to follow protocols, or defects in the protocols themselves'.
According to Amnesty International, the US executed 24 people in 2023, the third-highest number of confirmed executions in the world after Iran and Saudi Arabia. The US also had the fifth-highest number of death sentences, after China, Iran, Saudi Arabia and Somalia.
A 2024 Gallup poll found that 53 percent of people in the US still support the death penalty, while 43 percent disapprove. Those figures, however, represent some of the lowest levels of support on record, with favour dropping sharply over the last several decades.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Jazeera
4 hours ago
- Al Jazeera
Wegovy maker Novo Nordisk warns of layoffs as competition grows
Novo Nordisk's outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be unavoidable as competition heats up against its blockbuster obesity drug Wegovy amid rising pressure from rival Eli Lilly. Novo Nordisk – which became Europe's most valuable company, worth $650bn, last year on booming sales of Wegovy – is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year, in part due to compounders who have been allowed to make copycat drugs based on the same ingredients as Wegovy due to shortages. Novo Nordisk, which according to its website has 77,000 employees, cut its full-year sales and profit forecasts last week, wiping $95bn off its market value since. The slide is a vast and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the company is eyeing potential cost-cutting measures. Layoffs loom 'We probably won't be able to avoid layoffs,' Jorgensen told Danish broadcaster DR. 'When you have to adjust a company, there are some areas where you have to have fewer people, some [areas] where you have to be smaller.' He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs – known as GLP-1 receptor agonists – was of 'equal size to our business' and compounded versions of Wegovy were sold at a 'much lower price point'. In May, Novo Nordisk said it expected many of the roughly one million US patients using compounded GLP-1 drugs to switch to branded treatments after a US Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million US patients were still using compounded GLP-1s and that the company's lowered outlook has 'not assumed a reduction in compounding' this year. 'The obesity market is volatile,' Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of the firm's new full-year guidance range would be for 'unforeseen events', such as stronger pricing pressure in the US than forecast, he said. The lower end of the range would imply sales around 150 billion Danish krone ($23bn) in the second half of 2025, compared with 157 billion krone ($24.5bn) in the same period last year. Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest US prescription data for Wegovy. While the drug was overtaken earlier this year by rival Eli Lilly's Zepbound in terms of US prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36 percent in the US and more than quadrupled in markets outside the US compared to a year ago, Novo Nordisk said. While Wegovy's US pricing held steady in the quarter, the company expected deeper erosion in the key US market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo Nordisk was expanding its US direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar 'cash sales' directly to patients, outside of insurance channels, in some markets outside the US. Cost cuts Novo Nordisk reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said the company was acting to 'ensure efficiencies in our cost base' as it announced it would terminate eight research and development projects. 'There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence,' Jefferies analysts said in a note. Investors have questioned whether the company can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendations on the stock since last week. Shares in Novo Nordisk plunged 30 percent last week – their worst weekly performance in over two decades. The stock has continued to tumble since the market opened in New York. As of 12pm local time (16:00 GMT), the pharmaceutical giant was down by more than 3.3 percent.
Al Jazeera
12 hours ago
- Al Jazeera
Iran executes man accused of spying for Israel
Iran has executed a man accused of spying for Israel, state media reported. Rouzbeh Vadi allegedly passed on information about a nuclear scientist killed in Israel's June attacks on the Islamic Republic, the Iranian judiciary's news outlet Mizan reported. He was executed on Wednesday and had worked in one of Iran's 'important and sensitive organisations', Mizan said. Executions of Iranians convicted of spying for Israel have significantly increased this year, with at least eight death sentences carried out in recent months. Israel's attacks in June involved 12 days of air attacks, including several that targeted Iran's top generals and nuclear scientists, for which Iran retaliated with barrages of missiles and drones. Iran has since the war pledged swift trials for people arrested on suspicion of collaborating with Israel. Mizan reported that Vadi had 'committed a wide range of crimes against the country's internal and external security, which have caused severe disruption to public order'. Vadi was allegedly recruited online and met Mossad – the Israeli intelligence service – officers five times in Vienna, Austria. Separately, Iran hanged a member of the ISIL (ISIS) group on Wednesday after he was accused of plotting sabotage, Mizan also reported. Officials accused Mehdi Asgharzadeh of being a member of the group who participated in military training in Syria and Iraq before illegally entering Iran with a four-member team, who were killed in a fight with Iranian security, the news site reported. Authorities said Iran's Supreme Court upheld the sentences of lower courts and followed full legal procedures before executing both men, Mizan reported.
Al Jazeera
20 hours ago
- Al Jazeera
US charges Chinese nationals with illegally shipping Nvidia chips to China
Authorities in the United States have charged two Chinese citizens with shipping tens of millions of dollars worth of advanced Nvidia chips to China in breach of export controls. Chuan Geng and Shiwei Yang are alleged to have 'knowingly and willfully' exported the graphic processing units (GPUs) used to power artificial intelligence without authorisation from October 2022 to July 2025, the US Department of Justice said on Tuesday. Export records indicate that Geng and Yang, both 28, organised at least 21 shipments though their El Monte, California-based company ALX Solutions Inc to companies in Singapore and Malaysia, the justice department said. The exports included a December 2024 shipment of Nvidia H100 GPUs – described as the most powerful chip on the market – that was 'falsely labelled' and had not obtained the necessary licence from the US Commerce Department, the justice department said. According to prosecutors, ALX Solutions received payments from firms in Hong Kong and China, including a $1m sum from a China-based company in January 2024, rather than the companies that accepted the shipments. Prosecutors alleged that a search of ALX Solutions' office and Geng and Yang's phone last week had revealed 'incriminating communications', including communications about shipping chips to China through Malaysia to evade US export reestrictions. Geng and Yang face a maximum penalty of 20 years in prison if convicted under the Export Control Reform Act. Al Jazeera could not immediately locate the accused's lawyers for comment. Santa Clara, California-based Nvidia said the case showed that 'smuggling is a nonstarter.' 'We primarily sell our products to well-known partners, including OEMs, who help us ensure that all sales comply with US export control rules,' a company spokesperson said. 'Even relatively small exporters and shipments are subject to thorough review and scrutiny, and any diverted products would have no service, support, or updates.' The US government has banned the export on the most advanced chips to China amid a heated battle for technological supremacy between Washington and Beijing. US officials have claimed that restrictions, many of which were introduced under former US President Joe Biden, are needed to safeguard national security. China, which has hit back with its own export controls against the US, has accused Washington of undermining global trade and abusing its dominance in tech. Last month, Nvidia CEO Jensen Huang announced that Washington had agreed to reverse its ban on the sale of its H20 GPU to China following discussions with US President Donald Trump. Huang said the lifting of the export ban on the H20, which was specifically designed for the Chinese market and is less powerful than the H100, would encourage 'nations worldwide to choose America.'
